SP 12008
Alternative Names: SP12008Latest Information Update: 28 Jan 2023
At a glance
- Originator Spherium Biomed
- Class Immunoproteins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autoimmune disorders; Systemic lupus erythematosus
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for preclinical development in Autoimmune-disorders in Spain (Parenteral)
- 18 Jan 2021 Preclinical development is ongoing Autoimmune disorders in Spain (Spherium Biomed pipeline, January 2021)
- 28 Oct 2020 No recent reports of development identified for preclinical development in Autoimmune-disorders in Spain (Parenteral)